Loading…
Loading…
Boston Common Asset Management LLC bought a new position in argenex SE (NASDAQ: ARGX) in the first quarter, according to the company in its most recent filing with the SEC. The fund bought 3,753 shares of the company's stock, valued at approximately $2,741,000. Other large investors have also recently modified their holdings of
Artisan Mid Cap Fund portfolio generated strong absolute returns and outpaced the Russell Midcap® Growth Index. Within IT, several semiconductor holdings produced exceptional returns, with multiple positions rising more than 100% during the period. During the quarter, we initiated new positions in Entegris, Modine Manufacturing and C.H. Robinson Worldwide.
SAN FRANCISCO--(BUSINESS WIRE)--Chai Discovery, the AI company building a computer-aided design suite for molecules, today announced a collaboration agreement with argenx, a leading immunology innovation company. The collaboration will see argenx get access to Chai's AI platform and apply de novo antibody discovery across therapeutic targets. argenx has built one of biotechnology's most productive antibody engines, combining deep immunology expertise with a high-powered antibody engineering tea.
Here is how argenex SE (ARGX) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Fortrea Holdings Inc. (FTRE) and argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?
This profitable Netherlands-based biotech name has produced triple-digit quarterly earnings growth.
Live Updates Don't wait: the analyst who called NVIDIA in 2010 just revealed his top 10 AI stocks. See the full list FREE now. Wells Fargo's Q3 Outlook 51 minutes ago Live Wells Fargo is betting on a strong summer for stocks, telling clients the Q3 sets up nicely for a rally before midterm election... Live Nasdaq Composite: Markets Kick Off H2 2026 on Cautious Note amid Chip Stock Profit Taking
Argenx SE (NASDAQ:ARGX) stock has faced pressure after the company disclosed changes to the analysis plan for its ongoing Phase 3 Vyvgart study in myositis.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for ARGX and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.